MedWorm: Alfuzosin

ALFUZOSIN HYDROCHLORIDE EXTENDED RELEASE (Alfuzosin Hydrochloride) Tablet [Camber Pharmaceuticals]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 19 Jan 2012 05:00:00 +0100

Updated Date: Jan 19, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Tamsulosin Potently and Selectively Antagonizes Human Recombinant α(1A/1D)-Adrenoceptors: Slow Dissociation from the α(1A)-Adrenoceptor May Account for Selectivity for α(1A)-Adrenoceptor over α(1B)-Adrenoceptor Subtype.

Biological and Pharmaceutical Bulletin — Fri, 13 Jan 2012 09:48:02 +0100

In conclusion, tamsulosin potently and selectively antagonized α(1A/1D)-adrenoceptor ligand binding, and slowly dissociated from the α(1A)-adrenoceptor subtype. PMID: 22223340 [PubMed - in process] (Source: Biological and Pharmaceutical Bulletin)

Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms

Andrologia — Fri, 23 Dec 2011 05:00:00 +0100

SummaryLower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are frequently encountered in ageing males. We compared the efficacy of alfuzosin 10 mg alone or in combination with sildenafil 50 mg in the treatment of LUTS due to benign prostatic hyperplasia. One hundred male patients older than 45 years were randomized to two groups containing 50 patients each; one group receiving alfuzosin 10 mg and the other group alfuzosin 10 mg combined with sildenafil 50 mg. International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), prostate volume and post‐void residual urine were evaluated. The mean age was 60.2 ± 17.8. Mean data of evaluated parameters in both groups at the end of 3rd month compared with baseline values are given respective or...

Xatral Tablets (Alfuzosin hydrochloride)- Revised SPC

NeLM - SPC Changes — Thu, 01 Dec 2011 05:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes There have been significant updates to several sections of the SPC, including the following: Change to section 4.4 - Special warnings and precautions for Use Alfuzosin should be used with caution in patients with acute cardiac failure. Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of alfuzosin. There is a risk of cerebral ischemic disorders in patients with symptomatic or asymptomatic pre-existing cerebral circulatory disturbances, due to the fact that hypotension may develo...

Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia

BJU International — Fri, 25 Nov 2011 05:00:00 +0100

CONCLUSIONS• TWOC has become a standard practice worldwide for men with BPH and AUR.• In most cases, an α1‐blocker is prescribed before TWOC and significantly increases the chance of success.• Prolonged catheterization is associated with an increased morbidity. (Source: BJU International)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

ALFUZOSIN HYDROCHLORIDEtablet, Extended Release [Sun Pharma Global FZE]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 25 Nov 2011 05:00:00 +0100

Updated Date: Nov 25, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ALFUZOSIN HYDROCHLORIDEtablet, Extended Release [Golden State Medical Supply, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 15 Nov 2011 05:00:00 +0100

Updated Date: Nov 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Re: Medical Expulsive Therapy Using Alfuzosin for Patient Presenting With Ureteral Stone Less Than 10mm: A Prospective Randomized Controlled Trial

The Journal of Urology — Mon, 24 Oct 2011 04:00:00 +0100

L. H. Chau, D. C. Tai, B. T. Fung, J. C. Li, C. W. Fan and M. K. Li Urology Division, Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China (Source: The Journal of Urology)

Floppy Iris Risk Factors

Ophthalmology — Sat, 01 Oct 2011 04:00:00 +0100

We read with great interest the article by Chatziralli and Sergentanis entitled, “Risk Factors for Intraoperative Floppy Iris Syndrome: a Meta-analysis.” The authors found a hierarchy concerning α1-blockers in floppy iris syndrome (IFIS) occurrence, with tamsulosin having a 40-fold greater than the other compounds of the same family, i.e., alfuzosin, doxazosin, and terazosin. In addition, regarding the collateral factors, they concluded that “ . . . hypertension, but not diabetes mellitus, emerged as a risk factor for IFIS.” Consequently, a question arises: what is the weight of the therapy and that of the disease; in other words, is the disease per se, (hypertension) that leads to IFIS, or rather, is the therapy responsible for its occurrence? (Source: Ophthalmology)

E76 Efficacy of Alfuzosin (alpha blocker) after extra corporeal Shockwave lithotripsy for passage of renal calculi

European Urology Supplements — Sun, 11 Sep 2011 00:34:48 +0100

(Source: European Urology Supplements)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Imatinib Mesylate (Gleevec) as Protein-tyrosine Kinase Inhibitor Elicits Smooth Muscle Relaxation in Isolated Human Prostatic Tissue

Urology — Mon, 29 Aug 2011 04:00:00 +0100

Conclusion: Imatinib induced prostatic smooth muscle relaxation in vitro. This effect was suppressed by l-NAME and ODQ, showing a dependence on the nitric oxide-cyclic guanosine monophosphate pathway and modulated by the KATP and BKCa2+ K+ channels. Our findings suggest that imatinib can augment relaxation of human prostatic tissues by way of a novel ligand-protein tyrosine kinase signaling pathway. (Source: Urology)

Company launches generic version of alpha-blocker for BPH

Modern Medicine — Wed, 24 Aug 2011 23:00:00 +0100

Mylan Inc. recently announced that its subsidiary, Mylan Pharmaceuticals Inc., has launched alfuzosin hydrochloride extended-release tablets, 10 mg, for signs and symptoms of BPH. (Source: Modern Medicine)

Mylan Launches Generic Version of Uroxatral Tablets

Drugs.com - Pharma News — Fri, 12 Aug 2011 12:08:44 +0100

PITTSBURGH, Aug. 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg. This product is the generic version of... (Source: Drugs.com - Pharma News)

Mylan Launches Generic Version Of Uroxatral® Tablets

Pharmaceutical Online News — Fri, 12 Aug 2011 05:01:00 +0100

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg. (Source: Pharmaceutical Online News)

ALFUZOSIN HYDROCHLORIDEtablet, Extended Release [Apotex Corp.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 29 Jul 2011 05:00:00 +0100

Updated Date: Jul 29, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Torrent Pharma gets US FDA nod for generic Uroxatral

The Economic Times Healthcare and Biotech News — Wed, 20 Jul 2011 06:19:30 +0100

Torrent Pharmaceuticals Ltd has received U.S. Food and Drug Administration's approval for alfuzosin hydrochloride extended release tablets. (Source: The Economic Times Healthcare and Biotech News)

Sun Pharma gets USFDA nod to market generic Uroxatral tablets

The Economic Times Healthcare and Biotech News — Tue, 19 Jul 2011 08:39:58 +0100

The company's Alfuzosin Hydrochloride 10-mg tablets are therapeutically equivalent to drug-maker Sanofi-Aventis' Uroxatal extended release tablets. (Source: The Economic Times Healthcare and Biotech News)

ALFUZOSIN HYDROCHLORIDEtablet, Extended Release [Torrent Pharmaceuticals Limited]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 19 Jul 2011 05:00:00 +0100

Updated Date: Jul 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ALFUZOSIN HYDROCHLORIDE (Alfuzosin) Tablet, Extended Release [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 19 Jul 2011 05:00:00 +0100

Updated Date: Jul 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

ALFUZOSIN HYDROCHLORIDEtablet, Extended Release [Sun Pharma Global FZE]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 19 Jul 2011 05:00:00 +0100

Updated Date: Jul 19, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Chronic prostatitis

Clinical Evidence — Tue, 12 Jul 2011 23:00:00 +0100

New evidence; conclusions changed for: Alpha-blockers for chronic abacterial prostatitis/chronic pelvic pain syndrome New evidence added. Categorisation changed from Likely to be beneficial to Unknown effectiveness (as a new large RCT found no significant difference between alfuzosin and placebo, by contrast with previous, smaller trials). New evidence; conclusion confirmed for: Antimicrobial drugs (oral) for chronic bacterial prostatitis New evidence added. Categorisation unchanged (Likely to be beneficial). NSAIDs for chronic abacterial prostatitis/chronic pelvic pain syndrome New evidence added. Categorisation unchanged (Unknown effectiveness), as there remains insufficient evidence to judge this interve...

Treatment with a Uroselective α1‐Blocker Improves Voiding and Sexual Function: A Study in Thai Men with Lower Urinary Tract Symptoms

The Journal of Sexual Medicine — Wed, 22 Jun 2011 23:00:00 +0100

Conclusion. Treatment with 10 mg alfuzosin OD is safe and effective in improving voiding and sexual function in Thai men with LUTS and ED. Permpongkosol S, Krilad‐O‐Larn S, and Ratana‐O‐Larn K. Treatment with a uroselective α1‐blocker improves voiding and sexual function: A study in Thai men with lower urinary tract symptoms. J Sex Med **;**:**–**. (Source: The Journal of Sexual Medicine)

Alfuzosin: Hepatocellular lesion: case report

Reactions — Mon, 13 Jun 2011 16:21:55 +0100

(Source: Reactions)

Efficacy of three different alpha 1-adrenergic blockers and hyoscine N-butylbromide for distal ureteral stones

International Braz J Urol — Mon, 06 Jun 2011 16:04:03 +0100

CONCLUSIONS: Medical treatment of distal ureteral calculi with alfuzosin, doxazosin and terazosin resulted in a signi?cantly increased stone-expulsion rate and decreased expulsion time when compared with HBB. HBB seems to have a negative effect on stone-expulsion rate. (Source: International Braz J Urol)

Xatral and Xatral XL 10mg (alfuzosin) - Revised SPC

NeLM - SPC Changes — Wed, 01 Jun 2011 23:00:00 +0100

Source: eMC (electronic Medicines Compendium) Area: Other Library Updates > SPC Changes Section 4.2 of the SPCs for Xatral XL and Xatral have been updated to include that the efficacy of alfuzosin has not been demonstrated in children aged 2 to 16 years, and it is therefore not indicated for use in the paediatric population. Please see below for link to SPCs and full prescribing information.l (Source: NeLM - SPC Changes)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

Biomedical Chromatography : BMC — Wed, 18 May 2011 23:00:00 +0100

Authors: Sharma S, Dubey NK, Dasgupta AK, Sahu M, Benjamin B, Mullangi R, Srinivas NR A highly sensitive, rapid assay method has been developed and validated for the estimation of JI-101 in human plasma and urine using LC-MS/MS-ESI in the positive-ion mode. The assay procedure involves extraction of JI-101 and alfuzosin (internal standard, IS) from human plasma/urine with a solid-phase extraction process. Chromatographic resolution was achieved on two Zorbax SB-C(18) columns connected in series with a PEEK coupler using an isocratic mobile phase comprising acetonitrile-0.1% formic acid in water (70:30, v/v). The total run time was 2.0 min. The MS/MS ion transitions monitored were 466.20 → 265.10 for JI-101 and 390.40 → 156.10 for IS. The method was subjected to rigorous v...

Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: A prospective randomized controlled trial

International Journal of Urology — Sat, 30 Apr 2011 23:00:00 +0100

Conclusions: MET using alfuzosin SR 10 mg daily is effective to enhance the ureteral stone spontaneous passage rate, particularly for upper ureteral stones. Fewer analgesic drugs are consumed and more patients can avoid ureteroscopic lithotripsy and/or extracorporeal shock wave lithotripsy. (Source: International Journal of Urology)

Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia

International Urology and Nephrology — Thu, 07 Apr 2011 17:08:55 +0100

Conclusions Tam and Alf, which were used during different time frames in the same individuals, are associated with similarly favorable outcomes. When one alpha-blocker does not provide a desired effect in the treatment of BPH, switching to another alpha-blocker seems to be beneficial. Content Type Journal ArticlePages 1-6DOI 10.1007/s11255-011-9949-2Authors Erkan Karadağ, Urology Department, Yüksek İhtisas Education and Research Hospital, Bursa, TurkeySedat Öner, Urology Department, Yüksek İhtisas Education and Research Hospital, Bursa, TurkeyYasemin U. Budak, Clinical Laboratory Department, Sevket Yilmaz Education and Research Hospital, 16016 Yildirim, Bursa, TurkeyÖzcan Atahan, Urology Department, Yüksek İhtisas Education and Research Hospital, Bursa, Tur...

Meta‐analysis showing the beneficial effect of α‐blockers on ureteric stent discomfort

BJU International — Thu, 31 Mar 2011 23:00:00 +0100

CONCLUSION• There is evidence that α‐blockers provide an improvement in discomfort after placement of a ureteric stent. (Source: BJU International)

Alfuzosin: Thrombocytopenia (first report) in an elderly patient: case report

Reactions — Tue, 29 Mar 2011 16:01:27 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

The Long-term Effect of Alfuzosin in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia: Evaluation of Voiding and Storage Function With Respect to Bladder Outlet Obstruction Grade and Contractility

Urology — Mon, 24 Jan 2011 00:00:00 +0100

Objectives: To evaluate the efficacy of alfuzosin treatment on voiding and storage in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with respect to bladder outlet obstruction and contractility.Methods: A 12-month, multicenter, observational, prospective study was conducted at four university hospitals in Korea. Patients were divided into four groups: group 1 (bladder outlet obstruction index (BOOI) ≥20, bladder contractility index (BCI) ≥100), group 2 (BOOI ≥20, BCI (Source: Urology)

Comparison of Effects of Alpha Receptor Blockers on Endothelial Functions and Coagulation Parameters in Patients with Benign Prostatic Hyperplasia

Urology — Mon, 24 Jan 2011 00:00:00 +0100

Conclusions: Alpha receptor blockers can decrease the risk of cardiovascular complications by both reducing platelet aggregation and protecting endothelial functions in patients with prostatic hyperplasia. The only drug with a favorable effect in all 4 areas of interest, including BPH symptoms, blood pressure, platelet aggregation, and endothelial functions, was terazosin. (Source: Urology)

Most Bothersome Symptom and Symptom Specific Goal Achievement in Patients With Benign Prostatic Obstruction: A Prospective Open Label Study

The Journal of Urology — Wed, 19 Jan 2011 00:00:00 +0100

Conclusions: Assessing goal achievement for most bothersome symptoms can be a useful outcome measure in patients with benign prostatic obstruction with heterogeneous symptoms or goals reflecting change in quality of life. (Source: The Journal of Urology)

Risk Factors for Intraoperative Floppy Iris Syndrome: A Meta-Analysis

Ophthalmology — Tue, 21 Dec 2010 00:00:00 +0100

Conclusions: This meta-analysis has highlighted a hierarchy concerning the role of α1-blockers in IFIS, indicating an extremely sizeable effect size of tamsulosin; this may entail important physiologic implications. Alfuzosin, terazosin, and doxazosin presented with comparable effect sizes. Hypertension, but not diabetes mellitus, emerged as a risk factor for IFIS.Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. (Source: Ophthalmology)

Health supplement associated with intraoperative floppy-iris syndrome

Journal of Cataract and Refractive Surgery — Wed, 26 May 2010 13:52:56 +0100

Intraoperative floppy-iris syndrome (IFIS) during cataract surgery has become a well-known phenomenon over the past few years. Classically, it is described in association with α1-antagonists such as tamsulosin, alfuzosin, and doxazosin. The α1-adrenergic antagonist actions of other agents such as mianserin and labetalol have also been linked to IFIS. Recently, a dopamine agonist, ropinirole, was associated with IFIS. (Source: Journal of Cataract and Refractive Surgery)

NICE publishes clinical guideline on management of lower urinary tract symptoms in men

NeLM - Guidelines — Tue, 18 May 2010 23:00:00 +0100

Source: NICE Clinical Guideline Area: Evidence > Guidelines NICE has published a clinical guideline (CG97) on the effective management of lower urinary tract symptoms (LUTS) in men. In terms of drug treatment, NICE make the following recommendations: . Offer drug treatment only to men with bothersome LUTS when conservative management options have been unsuccessful or are not appropriate. . Take into account comorbidities and current treatment when offering drug treatment for LUTS. . Offer an alpha blocker (alfuzosin, doxazosin, tamsulosin or terazosin) to men with moderate to severe LUTS. . Offer an anticholinergic to men to manage the symptoms of overactive bladder. . Offer a 5-alpha reductase inhibitor to men with LUTS who have prostates est...

Uroxatral (Alfuzosin HCl) - updated on RxList

RxList - New and Updated Drug Monographs — Mon, 03 May 2010 07:00:00 +0100

Uroxatral (Alfuzosin HCl) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

FDA Releases New Drug-Drug Interaction Information for Approved Protease Inhibitors

Thu, 29 Apr 2010 23:00:00 +0100

“The approved protease inhibitors for the treatment of HIV-1 infection now all include the following drug-drug interaction information: Revatio (sildenafil) as a contraindicated medication when prescribed for the treatment of pulmonary arterial hypertension Uroxatral (alfuzosin) as a contraindicated medication Recommendation that salmeterol should not be coadministered New dosing recommendation for Tracleer (bosentan) and Adcirca (tadalafil) when prescribed for the treatment of pulmonary arterial hypertension. Note, coadministration of bosentan and Reyataz (atazanavir) without ritonavir is not recommended. New dosing recommendations for colchicine when prescribed for the treatment of familial Mediterranean fever or gout New dosing recommendations for colchicine when p...

UROXATRAL (Alfuzosin Hydrochloride) Tablet, Extended Release [Sanofi-Aventis U.S. LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 28 Apr 2010 05:00:00 +0100

Updated Date: Apr 28, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Alfuzosin Improves Ejaculatory Dysfunction in Men With Probable BPH

Medscape Today Headlines — Tue, 20 Apr 2010 18:58:31 +0100

The uroselective alpha-1-adrenergic blocker alfuzosin significantly improves lower urinary tract symptoms and symptoms of ejaculatory dysfunction in men with benign prostatic hypertrophy (BPH). Medscape Medical News (Source: Medscape Today Headlines)

1000 alfuzosin 10mg once daily improves ejaculatory dysfunction in real life practice: results of a 6-month study in 1681 men with luts suggestive of bph

European Urology Supplements — Mon, 29 Mar 2010 15:06:29 +0100

(Source: European Urology Supplements)

Investigating Contamination of Phytotherapy Products for Benign Prostatic Hyperplasia With α-Blockers and 5α-Reductase Inhibitors

The Journal of Urology — Fri, 19 Mar 2010 00:00:00 +0100

Conclusions: All phytotherapeutic agents for benign prostatic hyperplasia in this study tested negative for α-blockers and 5α-reductase inhibitors. Inconsistent results in trials using phytotherapeutic agents are probably not explained by the presence of standard pharmaceuticals. (Source: The Journal of Urology)

UROXATRAL (Alfuzosin Hydrochloride) Tablet, Extended Release [Stat Rx USA]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 15 Mar 2010 05:00:00 +0100

Updated Date: Mar 15, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Sexuality and Management of Benign Prostatic Hyperplasia with Alfuzosin: SAMBA Thailand

The Journal of Sexual Medicine — Mon, 08 Mar 2010 00:00:00 +0100

Conclusions. Alfuzosin 10 mg OD administered for 6 months provides a marked and rapid (within 1 week) improvement in LUTS and bother score while improving both ED and EjD. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N, Tongbai T, Wanamkang T, Lojanapiwat B, Permpongkosol S, Tantiwong A, Pripatnanont C, Akarasakul D, Kongwiwatanakul S, and Chotikawanich E. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med **;**:**[ndash]**. (Source: The Journal of Sexual Medicine)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

UROXATRAL (Alfuzosin Hydrochloride) Tablet [Stat Rx USA]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 02 Feb 2010 05:00:00 +0100

Updated Date: Feb 2, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Alfuzosin hydrochloride transdermal films: evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters